Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immunovant Inc IMVT

Healthcare Biotechnology
Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is... see more

Recent & Breaking News (NDAQ:IMVT)

Immunovant to Host Virtual R&D Day on March 30, 2022

GlobeNewswire March 28, 2022

Immunovant to Present at the 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 9, 2022

Immunovant Reports Financial Results for the Quarter Ended December 31, 2021

GlobeNewswire February 4, 2022

Immunovant Appoints Mark Levine as Chief Legal Officer

GlobeNewswire January 25, 2022

Immunovant to Present at the 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 7, 2022

Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022

GlobeNewswire December 30, 2021

Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference

GlobeNewswire November 12, 2021

Immunovant Reports Financial Results for the Quarter Ended September 30, 2021

GlobeNewswire November 5, 2021

Immunovant to Participate in Roivant R&D Day 2021

GlobeNewswire September 27, 2021

Immunovant Appoints Renee Barnett as Chief Financial Officer

GlobeNewswire September 15, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 20, 2021 - IMVT

Newsfile April 14, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 20, 2021 - IMVT

Newsfile April 12, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 20, 2021 - IMVT

Newsfile April 9, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 20, 2021 - IMVT

Newsfile April 7, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 20, 2021 - IMVT

Newsfile April 5, 2021

Rosen, Global Investor Counsel, Encourages Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation Investors to Secure Counsel Before Important April 20 Deadline - IMVT, HSACU, HSAC, HSACW

Newsfile April 1, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 20, 2021 - IMVT

Newsfile April 1, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 20, 2021 - IMVT

Newsfile March 30, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 20, 2021 - IMVT

Newsfile March 25, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 20, 2021 - IMVT

Newsfile March 22, 2021